CEO Guilty Plea Follows Seeger Weiss Whistleblower Case Against SpineFrontier

On May 15, 2025, SpineFrontier CEO Kingsley Chin pled guilty to federal criminal charges for making false statements to the Centers for Medicare & Medicaid Services (CMS), stemming from a qui tam action in which Seeger Weiss represents two of the relator whistleblowers. The underlying civil case helped precipitate this criminal matter, which alleged widespread […]

May 23, 2025

On May 15, 2025, SpineFrontier CEO Kingsley Chin pled guilty to federal criminal charges for making false statements to the Centers for Medicare & Medicaid Services (CMS), stemming from a qui tam action in which Seeger Weiss represents two of the relator whistleblowers. The underlying civil case helped precipitate this criminal matter, which alleged widespread kickback schemes within the medical device industry. 

Prosecutors claimed that Chin, along with SpineFrontier’s CFO, bribed surgeons through sham consulting arrangements that rewarded providers for using the company’s spinal implants—payments that allegedly totaled over $2.7 million. As part of that scheme, Chin directed employees to falsely report payments to surgeons as “consulting fees” when no actual consulting work was performed.  

Seeger Weiss has brought multiple cases that have resulted in criminal indictments, at least four of which resulted in a criminal conviction. 

“This case is yet another example of how whistleblowers can help drive systemic change,” said Stephen Weiss, founding partner of Seeger Weiss who brought the underlying qui tam suit. “Seeger Weiss continues to advocate for accountability and integrity in the healthcare system on behalf of its whistleblower clients, whose actions help expose fraud and catalyze government enforcement efforts.” 

Related News

July 28, 2026
Seeger Weiss Named Pharmaceutical Litigation Practice Group of the Year at the National Law Journal’s 2026 Elite Trial Lawyers Awards

Seeger Weiss has been named as Pharmaceutical Litigation Practice Group of the Year at the National Law Journal’s 2026 Elite Trial Lawyers Awards. This honor is reflects to the Seeger Weiss team’s efforts throughout the entire Pharmaceutical Litigation practice area, but specifically the firm’s work on the GLP-1 RA and Depo-Provera litigations. Partner Parvin Aminolroaya […]

Read More
July 28, 2026
Plaintiffs Reach Uncapped Global Settlement With J&J, Company to Pay Minimum of $5.8 Billion to Resolve Talc Litigation After More Than a Decade

The Plaintiffs’ Negotiation Committee in multi-district litigation 2738 (District of New Jersey), with the support and endorsement of the Plaintiffs’ Executive Committee and the Plaintiffs’ Steering Committee, announces today that it has reached a historic uncapped global settlement with J&J, Company to pay a minimum $5.8 billion settlement to resolve all current and pending talcum […]

Read More
June 29, 2026
Seeger Weiss Earns Tier 1 Ranking in the 2026 Legal 500 USA Guide

Seeger Weiss is proud to announce that the firm has been selected for a Tier 1 ranking in the 2026 Legal 500 USA Guide in the Product Liability, Mass Tort and Class Action: Plaintiff category. Founding Partner Christopher Seeger was selected for inclusion in the category’s Hall of Fame in recognition of his continued leadership […]

Read More